Logotype for Fluicell

Fluicell (FLUI) investor relations material

Fluicell Q3 2025 earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Fluicell
Q3 2025 earnings summary28 Nov, 2025

Executive summary

  • Revenue for Q3 2025 increased 138% year-over-year to 1,232 KSEK, driven by sales to The Francis Crick Institute and Ambusol, and higher consumables sales.

  • EBITDA for Q3 was -2,743 KSEK, and operating result was -2,832 KSEK, both lower than last year due to changes in revenue structure and accounting principles.

  • For the first nine months, revenue rose 61% to 2,166 KSEK, with total income up 69% to 9,441 KSEK, reflecting intensified development work and new accounting for R&D.

  • Strategic partnerships and project financing, notably with Breakthrough T1D and Ambusol, have strengthened the business outlook.

Financial highlights

  • Q3 2025 net sales: 1,232 KSEK (up from 517 KSEK); total income: 2,321 KSEK (down from 4,132 KSEK due to prior year one-off tax effect).

  • Q3 EBITDA: -2,743 KSEK; operating result: -2,832 KSEK; net result: -2,871 KSEK; EPS: -2.09 SEK.

  • Nine-month EBITDA: -8,017 KSEK; operating result: -8,300 KSEK; net result: -8,433 KSEK; EPS: -6.14 SEK.

  • Cash flow from operations improved to -1,230 KSEK in Q3 (from -4,111 KSEK); nine-month operating cash flow: -7,903 KSEK (from -17,359 KSEK).

  • Cash at period end: 990 KSEK (down from 17,575 KSEK year prior).

Outlook and guidance

  • 2026 forecasted result and cash flow in the range of -1 MSEK to 1 MSEK, indicating potential for positive cash flow.

  • Improved financial position and cost structure support growth and business development, with focus on diabetes and cancer programs.

  • Management sees strong opportunities in new product initiatives and expects to strengthen market presence.

Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.

Next Fluicell earnings date

Logotype for Fluicell
Q4 202520 Feb, 2026
Your earnings 
season toolkit.
Download
Free on both iOS & Android.

Next Fluicell earnings date

Logotype for Fluicell
Q4 202520 Feb, 2026

The essential earnings season companion

The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.

Live calls and transcripts

Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.

Find what you need faster

Search for any keyword across all transcripts simultaneously.

Easily store key findings

Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Your watchlist. Your dashboard.

Follow the companies that matter to you. Get a personalized feed with real-time updates.

Be the first to know

Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.

Consensus estimates

Access analyst consensus estimates, valuation multiples, and revenue segments splits.

All IR material in one place

The easiest way to stay updated during earnings season.

Global coverage

All events from public companies. Live and recorded.

Just click and listen

No webcast links. No manual registrations.

Research anytime, anywhere

Built for professionals. Loved by everyone. Try our free mobile app.

excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com

Frequently asked questions

Fluicell is a biotech company that specializes in pioneering solutions for bioprinting and single-cell biology. Established in 2012 as a spin-off from Chalmers University of Technology in Gothenburg, Sweden, Fluicell has developed a reputation for its innovative approach to studying and manipulating individual cells with precision. The company's flagship technology, Biopixlar, is a high-resolution 3D bioprinting platform capable of constructing biological tissues at the single-cell level without the need for bioink. This technology is utilized in the development of tissue-based therapies for serious diseases lacking adequate treatments, such as type 1 diabetes, cardiovascular disease, and kidney disease.

Quartr provides global coverage of all investor relation material from public companies.

  • Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

  • Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.

  • Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.

Yes, the Quartr mobile app is free on both iOS and Android.

Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.

Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.

Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.

Explore our global coverage